NASHVILLE, Tenn.--(BUSINESS WIRE)--The Sarah Cannon Blood Cancer Network announced today that 15 abstracts have been accepted for presentation at the 2015 BMT Tandem Meetings held Feb. 11-15 in San Diego, Calif. The presentations, which represent clinicians from its network of transplant programs across the nation, are centered on the effectiveness and treatment standards of blood and marrow transplantation (BMT) for various types of blood disorders.
“The abstracts focus on cutting-edge research, standardization of care and new, innovative processes that benefit blood cancer patients,” said Howard A. “Skip” Burris, III MD, President, Clinical Operations for Sarah Cannon. “The diversity of these abstracts demonstrates our unwavering commitment to advancing therapies for blood cancer patients.”
Members of the Sarah Cannon Blood Cancer Network comprise a multidisciplinary team of physicians and staff from six FACT accredited blood cancer programs. Of the 15 abstracts accepted, 10 highlight the network’s collaboration on the standardization of clinical pathways, standard operating procedures and BMT processes that support improved outcomes.
“Sarah Cannon Blood Cancer Network brings together leaders in the field of BMT seeking to transform the patient experience within blood and marrow transplantation,” said C. Fred LeMaistre, MD, Senior Vice President, Sarah Cannon Market Operations and Physician in Chief of Blood Cancers and past president of ASBMT. “We are excited to connect with our research colleagues at the BMT Tandem meeting as we work together to improve practice standards for patients around the world.”
The combined annual meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) bring together thousands of physicians, investigators and other healthcare professionals to discuss blood and marrow transplantation, research, education and clinical standards.
About The Sarah Cannon Blood Cancer Network
The Sarah Cannon Blood Cancer Network is one of the largest providers of blood cancer care including blood and marrow transplantation (BMT) across the United States and United Kingdom. Its network conducts over 900 transplants annually and has treated more than 10,000 patients since the inception of our first program. Through its commitment to the highest level of quality standards, infrastructure, training and research, the Sarah Cannon Blood Cancer Network provides an unparalleled experience for patients seeking treatment. For more information about the Blood Cancer Network and Sarah Cannon’s full suite of cancer services, please visit: sarahcannon.com.
About Sarah Cannon
Sarah Cannon, the global cancer enterprise of Hospital Corporation of America (HCA), offers cutting-edge clinical research alongside integrated cancer services. From discovery to recovery, Sarah Cannon provides patients convenient access to world-class cancer care with more than 75 accredited centers across the US and UK. Sarah Cannon’s cancer programs include individualized patient navigation provided by oncology-trained nurses, more than 900 stem cell transplants performed annually throughout the Sarah Cannon Blood Cancer Network, more than 500 clinical trials, and molecular profiling capabilities. Through its services, Sarah Cannon is providing state-of-the- art cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center. To learn more about Sarah Cannon, visit sarahcannon.com.